- Home
- FGB vs KPTI Comparison
FGB vs KPTI Comparison
Compare FGB & KPTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FGB
- KPTI
- Stock Information
- Founded
- FGB 2007
- KPTI 2008
- Country
- FGB United States
- KPTI United States
- Employees
- FGB N/A
- KPTI N/A
- Industry
- FGB Finance/Investors Services
- KPTI Biotechnology: Pharmaceutical Preparations
- Sector
- FGB Finance
- KPTI Health Care
- Exchange
- FGB Nasdaq
- KPTI Nasdaq
- Market Cap
- FGB 60.1M
- KPTI 54.4M
- IPO Year
- FGB N/A
- KPTI 2013
- Fundamental
- Price
- FGB $3.88
- KPTI $6.40
- Analyst Decision
- FGB
- KPTI Strong Buy
- Analyst Count
- FGB 0
- KPTI 5
- Target Price
- FGB N/A
- KPTI $61.00
- AVG Volume (30 Days)
- FGB 53.0K
- KPTI 84.2K
- Earning Date
- FGB 01-01-0001
- KPTI 05-20-2025
- Dividend Yield
- FGB 8.92%
- KPTI N/A
- EPS Growth
- FGB N/A
- KPTI N/A
- EPS
- FGB N/A
- KPTI N/A
- Revenue
- FGB N/A
- KPTI $145,237,000.00
- Revenue This Year
- FGB N/A
- KPTI $4.87
- Revenue Next Year
- FGB N/A
- KPTI $16.29
- P/E Ratio
- FGB N/A
- KPTI N/A
- Revenue Growth
- FGB N/A
- KPTI N/A
- 52 Week Low
- FGB $2.85
- KPTI $3.51
- 52 Week High
- FGB $3.74
- KPTI $18.00
- Technical
- Relative Strength Index (RSI)
- FGB 47.05
- KPTI 55.45
- Support Level
- FGB $3.76
- KPTI $5.90
- Resistance Level
- FGB $3.87
- KPTI $7.90
- Average True Range (ATR)
- FGB 0.07
- KPTI 0.66
- MACD
- FGB 0.02
- KPTI 0.07
- Stochastic Oscillator
- FGB 68.00
- KPTI 40.29
About FGB First Trust Specialty Finance and Financial Opportunities Fund
First Trust Specialty Fnc & Fncl Oppor is a United States-based closed-end management investment company. The Fund's primary investment objective is to seek a high level of current income. It seeks a positive total return as a secondary objective. The Fund seeks to achieve its investment objectives by investing at least 80% of its Managed Assets in a portfolio of securities of specialty finance and other financial companies.
About KPTI Karyopharm Therapeutics Inc.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.